Literature DB >> 7120875

Ectopically produced calcitonin in human hemoblastoses.

K H Pflüger, C Gropp, K Havemann.   

Abstract

The incidence of elevated serum levels of immunoreactive calcitonin (CT) in human myeloproliferative and lymphoproliferative disorders was investigated. On the basis of twice the normal range, about 45% of patients with acute leukemia and blast crisis of chronic myelocytic leukemia (CML) showed elevated serum levels of CT. Markedly elevated levels (greater than 1,000 pg/ml) were only found in this group. Since immunoreactive CT dropped to normal or only slightly elevated levels in remission and increased again before or during relapse, serum CT levels seem to reflect the activity of the disease. However, in patients with chronic leukemia, Hodgkin's and non-Hodgkin's lymphoma, a lower incidence and only slightly elevated serum levels were found. In addition, the molecular weight of the proteohormone in serum specimen and cell extracts was investigated by gel chromatography. Besides physiological CT, different high-molecular weight forms of the hormone could be demonstrated in serum and in cell extracts. Extracts of leukemic cells revealed higher molecular forms only. It is suggested that the proteohormone is ectopically produced by leukemic cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7120875     DOI: 10.1007/bf01716799

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  24 in total

1.  Calcitonin is not contained within the common precursor to corticotropin and endorphin in the rat.

Authors:  E Weber; K H Voigt; R E Mains; B A Eipper
Journal:  Biochem Biophys Res Commun       Date:  1979-07-27       Impact factor: 3.575

2.  Epidemiology of medullary carcinoma of the thyroid gland: a 5-year experience (1971-1976).

Authors:  G W Sizemore; J A Carney; H Heath
Journal:  Surg Clin North Am       Date:  1977-08       Impact factor: 2.741

3.  Immunochemical heterogeneity of calcitonin in renal failure.

Authors:  J C Lee; J G Parthemore; L J Deftos
Journal:  J Clin Endocrinol Metab       Date:  1977-09       Impact factor: 5.958

4.  Plasma-immunoreactive-calcitonin in patients with non-thyroid tumours.

Authors:  R C Coombes; C Hillyard; P B Greenberg; I MacIntyre
Journal:  Lancet       Date:  1974-06-01       Impact factor: 79.321

5.  A radioimmunoassay for human calcitonin M.

Authors:  M B Clark; G W Boyd; P G Byfield; G V Foster
Journal:  Lancet       Date:  1969-07-12       Impact factor: 79.321

6.  Precursor molecule for calcitonin.

Authors:  J A van der Donk; R H van Dam; J Goudswaard; W H Hackeng; C J Lips
Journal:  Lancet       Date:  1976-11-20       Impact factor: 79.321

7.  ACTH, ADH, and calcitonin concentrations as markers of response and relapse in small-cell carcinoma of the lung.

Authors:  M Hansen; M Hammer; L Hummer
Journal:  Cancer       Date:  1980-11-01       Impact factor: 6.860

8.  Biosynthesis of human calcitonin: evidence for a prohormone.

Authors:  A Jullienne; N Segond; C Calmettes; M S Moukhtar; G Milhaud
Journal:  Biochem Biophys Res Commun       Date:  1980-08-14       Impact factor: 3.575

9.  Hypercalcitoninemia in pancreatitis--evidence for immunochemical heterogeneity.

Authors:  D B Cannarozzi; R K Donabedian
Journal:  Experientia       Date:  1977-04-15

10.  Immunochemical heterogeneity of calcitonin in plasma of patients with medullary thryoid carcinoma.

Authors:  G W Sizemore; H Hpeath; J M Larson
Journal:  J Clin Invest       Date:  1975-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.